NasdaqGM - Delayed Quote USD
SCYNEXIS, Inc. (SCYX)
At close: November 1 at 4:00 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,666.0000
140,141.0000
5,091.0000
13,163.0000
--
Cost of Revenue
15,062.0000
15,624.0000
628.0000
312.0000
--
Gross Profit
-5,396.0000
124,517.0000
4,463.0000
12,851.0000
--
Operating Expense
46,513.0000
51,848.0000
90,220.0000
73,689.0000
50,815.0000
Operating Income
-51,909.0000
72,669.0000
-85,757.0000
-60,838.0000
-50,815.0000
Net Non Operating Interest Income Expense
2,633.0000
-2,170.0000
-5,372.0000
-3,939.0000
-2,193.0000
Other Income Expense
14,547.0000
-3,320.0000
23,620.0000
28,823.0000
-5,325.0000
Pretax Income
-34,729.0000
67,179.0000
-67,509.0000
-35,954.0000
-58,333.0000
Tax Provision
661.0000
138.0000
-4,700.0000
-3,088.0000
-3,148.0000
Net Income Common Stockholders
-35,390.0000
67,041.0000
-62,809.0000
-32,866.0000
-55,185.0000
Diluted NI Available to Com Stockholders
-36,437.0000
67,041.0000
-62,809.0000
-32,866.0000
-55,185.0000
Basic EPS
-0.74
1.40
-1.47
-1.25
-5.15
Diluted EPS
-0.74
1.39
-1.47
-1.25
-5.15
Basic Average Shares
48,143.5960
47,852.8330
42,613.5100
26,384.7130
10,720.2110
Diluted Average Shares
48,143.5960
48,390.5820
42,613.5100
26,384.7130
10,720.2110
Total Operating Income as Reported
-51,909.0000
72,669.0000
-85,757.0000
-60,838.0000
-51,149.0000
Total Expenses
61,575.0000
67,472.0000
90,848.0000
74,001.0000
50,815.0000
Net Income from Continuing & Discontinued Operation
-35,390.0000
67,041.0000
-62,809.0000
-32,866.0000
-55,185.0000
Normalized Income
-46,882.1300
70,357.6800
-84,781.7763
-59,284.7700
-50,731.2110
Interest Income
5,031.0000
3,954.0000
1,415.0000
24.0000
189.0000
Interest Expense
838.0000
3,130.0000
5,198.0000
2,660.0000
1,181.0000
Net Interest Income
2,633.0000
-2,170.0000
-5,372.0000
-3,939.0000
-2,193.0000
EBIT
-33,891.0000
70,309.0000
-62,311.0000
-33,294.0000
-57,152.0000
EBITDA
-33,615.0000
70,889.0000
-61,705.0000
-32,915.0000
-57,041.0000
Reconciled Cost of Revenue
15,062.0000
15,624.0000
628.0000
312.0000
--
Reconciled Depreciation
276.0000
580.0000
606.0000
379.0000
111.0000
Net Income from Continuing Operation Net Minority Interest
-35,390.0000
67,041.0000
-62,809.0000
-32,866.0000
-55,185.0000
Total Unusual Items Excluding Goodwill
14,547.0000
-3,320.0000
23,617.0000
28,810.0000
-4,723.0000
Total Unusual Items
14,547.0000
-3,320.0000
23,617.0000
28,810.0000
-4,723.0000
Normalized EBITDA
-48,162.0000
74,209.0000
-85,322.0000
-61,725.0000
-52,318.0000
Tax Rate for Calcs
0.0002
0.0000
0.0001
0.0001
0.0001
Tax Effect of Unusual Items
3,054.8700
-3.3200
1,644.2237
2,391.2300
-269.2110
12/31/2020 - 5/2/2014
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
AKBA Akebia Therapeutics, Inc.
1.6900
+1.81%
DERM Journey Medical Corporation
6.17
+7.30%
SIGA SIGA Technologies, Inc.
7.21
-0.14%
ORGO Organogenesis Holdings Inc.
2.7800
+0.36%
AVDL Avadel Pharmaceuticals plc
15.05
-2.71%
OPTN OptiNose, Inc.
0.6760
-2.03%
IRWD Ironwood Pharmaceuticals, Inc.
4.1900
+6.08%
AQST Aquestive Therapeutics, Inc.
5.52
+0.55%
ELTP Elite Pharmaceuticals, Inc.
0.5000
+1.01%
CPHI China Pharma Holdings, Inc.
0.2565
-0.77%